Fibrinogen solution and thrombin solution for fibrin sealant and fibrin sealant kit

By adding additives such as guanine and cyclodextrin to the fibrin gel, the problem of increasing viscosity during storage at room temperature is solved, and stability at room temperature and simplicity before use is achieved, and the flexibility and effectiveness of use are improved.

JP2025504260APending Publication Date: 2025-02-07BAXTER INT INC +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024539438
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-30
Filing Date
2022-12-09
Publication Date
2025-02-07

AI Technical Summary

Technical Problem

In the prior art, the steps of the current fibrin glue that require thawing and heating before use are relatively cumbersome, resulting in inconvenience in use, and the viscosity increases when stored at room temperature for a long time, affecting the flexibility of use.

Method used

Fibrin stock and thrombin solutions were developed at room temperature to reduce the viscosity increase during storage by adding pharmaceutically acceptable additives such as guanine and cyclodextrin and maintain other beneficial properties such as mixing with thrombin solutions to form an opaque curing effect.

Benefits of technology

The stability of fibrin glue for long-term storage at room temperature and the simplicity before use is achieved, the freeze-thaw and heating steps are reduced, and the flexibility and effectiveness of use is improved.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

A fibrinogen solution and a thrombin solution are disclosed. The fibrinogen solution comprises fibrinogen at a concentration of at least 40 mg / ml, factor XIII, a pharma- ceutically acceptable additive, and water. The kinetic viscosity of the fibrinogen solution measured at 20°C increases by up to 35% after storing the fibrinogen solution at 20°C for 30 days. The thrombin solution comprises thrombin, a pharma- ceutically acceptable additive, and water. The thrombin activity decreases by up to 15% after storing the thrombin solution at 25°C for 14 days. A fibrin sealant kit is also disclosed, comprising a first container comprising the fibrinogen solution and a second container comprising the thrombin solution. Additionally, methods of preparing the fibrin sealant and methods of treating wounds are also disclosed.
Need to check novelty before this filing date? Find Prior Art